Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-07-29

FDA Approved: FOSAPREPITANT — Original Application (NorthStar RxLLC)

View source ↗

Summary

FDA approved the original application for fosaprepitant dimeglumine (fosaprepitant) from NorthStar RxLLC to prevent chemotherapy-induced nausea and vomiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

ORIG AP for FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)